First line imatinib—results of the IRIS study at 24 and 42 months of follow-up.
| . | CHR . | MCR . | CCR . | PFS . | ||||
|---|---|---|---|---|---|---|---|---|
| Abbreviations: CHR, complete hematologic response; MCR, major cytogenetic response; CCR, complete cytogenetic response; NR, not reported; PFS, progression-free survival. | ||||||||
| Months follow-up | 24 | 42 | 24 | 42 | 24 | 42 | 24 | 42 |
| Estimated rate (%) | NR | 98 | 88 | 91 | 79 | 84 | 96 | 94 |
| . | CHR . | MCR . | CCR . | PFS . | ||||
|---|---|---|---|---|---|---|---|---|
| Abbreviations: CHR, complete hematologic response; MCR, major cytogenetic response; CCR, complete cytogenetic response; NR, not reported; PFS, progression-free survival. | ||||||||
| Months follow-up | 24 | 42 | 24 | 42 | 24 | 42 | 24 | 42 |
| Estimated rate (%) | NR | 98 | 88 | 91 | 79 | 84 | 96 | 94 |